The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

NCT ID: NCT03077347

Last Updated: 2024-06-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-01

Study Completion Date

2023-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to better understand the neural correlates of cognitive control (CC) deficits in schizophrenia and determine how these mechanisms can be modulated by transcranial direct current stimulation (tDCS). CC is a critical neurocognitive process that is required for flexible, directed thought and action based on goals and intentions. Identifying and developing paradigms to improve CC is therefore a mental health priority. Current theories of CC postulate that recruitment of the dorsolateral prefrontal cortex (DLPFC) is essential for this process by maintaining high-level information that it can then use to orchestrate patterns of activation in other brain networks to support optimal performance. tDCS is a safe, noninvasive method of modulating regional brain excitability via brief (15-20 m) application of a weak (1-2 mA) current. The goal of the proposed experiments is to combine tDCS with functional magnetic resonance imaging (fMRI) to test the hypotheses that 1) acute tDCS over the DLPFC can improve performance during a CC task (the dot pattern expectancy (DPX) variant of the AX-Continuous Performance Task) in schizophrenia patients and healthy control subjects, and 2) acute tDCS over the DLPFC can increase recruitment of the DLPFC during the DPX. Effects of tDCS on brain functional connectivity (during CC as well as during the resting state) will also be examined, as well as effects on an episodic memory task. The current study will be the first to use functional magnetic resonance imaging (fMRI) to examine the effects of tDCS on the neuronal mechanisms of CC in schizophrenia, and has potentially important implications for therapeutic development for this treatment refractory yet disabling aspect of the illness.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Sham Stimulation followed by Direct Current Stimulation or Vice-Versa
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham Followed by Experimental Stimulation

Sham stimulation administered followed by 24-48 hour washout, then experimental stimulation.

Experimental Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex Placebo Comparator. 1 minute of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19 minutes of sham stimulation.

Group Type OTHER

Transcranial Direct Current Stimulation

Intervention Type DEVICE

In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Experimental Stimulation Followed by Sham

Experimental stimulation administered followed by 24-48 hour washout, then sham stimulation.

Experimental Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex Placebo Comparator. 1 minute of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19 minutes of sham stimulation.

Group Type OTHER

Transcranial Direct Current Stimulation

Intervention Type DEVICE

In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Direct Current Stimulation

In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

tDCS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sufficient English literacy so as to be able to understand and complete cognitive tasks.
* The ability to give valid informed consent.
* Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (for patient group)
* Stable outpatient or partial hospital status (for patient group)

Exclusion Criteria

* Psychiatric medication changes in the prior month (for patient group)
* No psychiatric medication changes anticipated in the upcoming month (for patient group)
* Intelligence Quotient (IQ) \< 70; IQ will be measured by administering the Wechsler Abbreviated Scale of Intelligence (WASI) test.
* People under the age of 18
* Pregnant Women
* Prisoners
* Pacemakers
* Implanted brain stimulators
* Implanted defibrillator
* Metallic implants
* Skin damage or skin conditions such as eczema at the sites where electrodes will be placed
* Dreadlocks or other hair styles hindering the placement of tDCS electrodes
* Cranial pathologies
* Head trauma
* Epilepsy
* Mental retardation
* Neurological disorders
* Uncorrected vision problems that would hinder cognitive testing (this also pertains to subjects with color blindness in tasks where discriminating colored objects/items is necessary for successful performance).
* Other than nicotine, no subjects reporting substance dependence in the past six months and no substance abuse in the past month
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Davis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cameron Carter, M.D.

Role: STUDY_DIRECTOR

University of California, Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Imaging Research Center, University of California Davis Medical Center

Sacramento, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1016455

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

tDCS to Enhance Cognitive Training in Schizophrenia
NCT01733602 COMPLETED PHASE1/PHASE2